No Data
No Data
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Bristol Myers Stock (NYSE:BMY): Perfect Place to Wait Out Market Volatility
Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ
Evotec Gets $25 Million From Bristol Myers Squibb Partnership
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Evotec Advances Strategic Neuroscience Partnership With Bristol Myers Squibb, Earning $25M Milestone Payment